Personalis, Inc. PSNL

Company Overview

Personalis, Inc. is a publicly traded genomics and biotechnology company that develops and provides advanced DNA sequencing technologies focused on ultra‑high‑accuracy genomic analysis. The company operates primarily in the genomics, precision medicine, and biopharmaceutical research industries, with a core emphasis on detecting rare genetic variants and low‑frequency mutations that are difficult to identify using standard sequencing approaches. Its offerings are designed to support applications in cancer research, minimal residual disease (MRD) detection, and population‑scale genomics studies.

The company’s primary revenue drivers are high‑accuracy sequencing services and related genomic data products sold to biopharmaceutical companies, academic institutions, and government agencies. Personalis is differentiated by its proprietary ACE Technology (Accuracy and Content Enhanced), which combines optimized laboratory processes with advanced bioinformatics to achieve significantly improved sequencing accuracy at scale. Personalis was founded in 2011 by Stephen Quake, a Stanford University professor and genomics pioneer, and initially focused on large‑scale human genome sequencing before evolving toward ultra‑deep, application‑specific sequencing for research and clinical development use cases.